Commercial Space Company Risk / Opportunity Ranking

Thesis: The reviewed sources only gives contextual membership rationale that Emposat provides ground-station access used in connection with a surveillance satellite, which is too indirect to support a durable positive investment thesis without direct within the recent evidence window business evidence.

Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Emposat.

Caveats: Phase-2 membership rationale references articles and, but the reviewed sources provide no for citation. Ground-station context is indirect and not enough for a strong thesis under the evidence standard.

Thesis: Insufficient admissible reviewed sources evidence to support a positive thesis within the selected recent evidence window, despite membership rationale describing EnduroSat as a space infrastructure and satellite-constellation builder.

Why now: Why now is unsupported because no evidence remain after recent evidence filtering; there is no dated catalyst, financing, contract, production, or customer evidence available here.

Caveats: No surviving evidence after recent evidence filtering. Reviewed evidence counts indicate evidence existed upstream, but none is included here for direct citation. Low scores reflect missing evidence, not a fundamental negative judgment.

Thesis: No positive thesis is supportable from the scoring evidence fields because no direct positive evidence are provided.

Why now: Why now is stronger than for most names here because the phase2 rationale specifically ties EON Space Labs to a PSLV failure context via article: implying a concrete event rather than generic company context. However, conviction remains low because the reviewed sources omits the underlying event summary and dates in the evidence exposed here.

Caveats: The adverse signal appears only in phase2 rationale, not in direct negative evidence. No article summary, quote, or timing detail is provided in the scoring fields. Impact magnitude on EON specifically cannot be quantified from these reviewed sources alone.

Thesis: The reviewed sources' membership rationale says FOSSA Systems has launched 24 satellites, is deploying an 80-satellite constellation, and has defense customers, but there are no available direct positive evidence or dated representative articles within the reviewed sources for scoring, so opportunity remains only a watchlist possibility.

Why now: No within the recent evidence window evidence are available after filtering, so there is no near-dated trigger or state change that can be scored from the local reviewed sources.

Caveats: Membership support references article, but that article content is not available here for direct citation. Coverage debug shows zero evidence after recent evidence window. A positive thesis requires positive evidence, not just category fit or membership rationale.

Thesis: The company belongs in the cohort as an Earth observation / SAR startup, but these reviewed sources provide no available within the recent evidence window directional evidence to support a strong 1 year+ opportunity thesis.

Why now: There is no within the recent evidence window evidence available for this entity in the reviewed sources; recency of any business progress is uncertain.

Caveats: Evidence recent evidence review shows 0 kept rows after the 90-day cutoff for this entity. Membership rationale references article IDs, and: but no article summaries or direct evidence are included in these reviewed sources for citation-level use. Scores are constrained by absence of directional evidence, not by a proven negative business outcome.

Thesis: No reviewed sources-supported positive thesis is available. The company is only described as appearing in generic 'space stocks' context, while direct positive evidence after the 90-day recent evidence window is absent.

Why now: There is no current catalyst in the reviewed sources. Coverage shows 32 article IDs considered but zero article IDs after recent evidence window and zero evidence after recent evidence window, so recency-based ranking is not supported.

Caveats: Phase2 rationale says only generic stock-screener style article context was available, citing article IDs, and, but no were provided in the reviewed sources. Evidence recent evidence review shows no current evidence was retained and undated_rows_kept = 0. Without for the cited membership-support articles, they cannot be used as factual thesis evidence under the citation requirement.

Thesis: Insufficient retained local evidence within the 90-day recent evidence window to support a positive 1 year+ opportunity thesis.

Why now: No company-specific dated evidence were retained after the 90-day recent evidence window cutoff of March 29, 2026, so there is no current catalyst basis in the reviewed sources.

Caveats: Reviewed evidence shows 64 articles considered but 0 article IDs after recent evidence window and 0 evidence retained. Membership support cited article IDs: and: but no article summaries or retained evidence are provided in these reviewed sources, so no factual thesis claims can be grounded from them.

Thesis: The reviewed sources offers no direct positive company-specific evidence within the available scoring set. The membership rationale says Hensoldt appears in a market report as one of many key players in the space situational awareness market, but that is article-level market-list context rather than direct business evidence, and no available evidence remain after recent evidence window.

Why now: No near-term or durable catalyst is established from the available evidence. Coverage debug shows 69 article IDs considered but 0 after recent evidence window and 0 evidence after dedupe.

Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Only context-level market-list mention is described, not a direct event or fact.

Thesis: A limited positive angle exists because the membership rationale says a HEO camera achieved sub-5-meter resolution in Sidus Space's earnings context, implying technical relevance (: and: unavailable in reviewed sources). However, this appears indirect and counterparty/component context rather than direct company evidence, so opportunity remains low.

Why now: Why now is weak because the cited technical-performance context is indirect, and the reviewed sources explicitly warns that relations are context-only and should not be used as counterparty propagation evidence.

Caveats: No current evidence is provided for: and Counterparty/component context is not strong direct evidence for HEO USA itself. Zero evidence available after recent evidence window.

Thesis: No direct positive evidence is available. The reviewed sources say Hermeus is only mentioned as one of several companies expanding in California in an article about Skydio, which is too indirect to support a durable positive thesis.

Why now: There is no current timing signal from the reviewed sources. Coverage debug shows 29 article IDs considered but 0 after recent evidence window and 0 evidence available.

Caveats: Membership rationale references article ID, but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. The only described mention is indirect article context.

Thesis: The reviewed sources places HughesNet within satellite broadband and communication services context via EchoStar, but there is no direct reviewed evidence in the 90-day window to support a differentiated 1 year+ opportunity thesis.

Why now: There is no validated near-term or long-term catalyst from active evidence. The reviewed sources cites article in membership support, but the company coverage section shows zero articles after recent evidence window and zero evidence after recent evidence window, so recency-backed thesis formation is not possible.

Caveats: High article count does not equal conviction; no post-recent evidence window evidence was available. No direct company-specific event/fact evidence is available in the output reviewed sources.

Thesis: There is no direct positive evidence in the available scoring set. The reviewed sources say Impulso is mentioned only as GalaxEye's distribution agreement counterparty, which does not establish Impulso's own business opportunity.

Why now: No timing catalyst is supported by the reviewed sources. Coverage debug shows 1 article considered but 0 after recent evidence window and 0 evidence available.

Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Counterparty context cannot be propagated into a direct thesis.

Thesis: Potential long-horizon opportunity exists if the previously referenced multi-launch agreement for servicing satellites remains active, but the reviewed sources provide no retained within the recent evidence window positive evidence to support a current thesis.

Why now: There is no qualifying 90-day retained evidence. The only cited article mentioning Infinite Orbits is dated September 16, 2025, outside the reviewed sources' 90-day recent evidence window, so recency for any business progress is not established.

Caveats: Reviewed evidence shows zero evidence retained after recent evidence window. Do not use the older TechCrunch article as current recency proof. Absence of recent negative evidence is not positive evidence.

Thesis: No current positive thesis is supportable within the reviewed sources' retained recent evidence window evidence.

Why now: Why now is weak because the only specific company article summary in the reviewed sources were dated February 23, 2026 and was dropped by the 90-day recent evidence window, so it cannot support current ranking despite mentioning financing and a Space Force contract, February 23, 2026).

Caveats: The reviewed sources contain a representative article summary for stating Integrate 'closed a $17M Series A and landed a $25M space force contract to deploy secure program management software,' but the evidence recent evidence review says those rows were dropped as older than the March 29, 2026 cutoff, so they are not usable for current scoring. The company may be space-adjacent software rather than a direct space operator, per the reviewed sources' own membership rationale.

Thesis: No positive thesis can be supported from retained evidence because the reviewed sources contain no direct positive rows within the recent evidence window.

Why now: No current catalyst is evidenced in retained rows.

Caveats: Phase-2 rationale says ILS provides engineering, mission design, range integration, and support for the STARLAUNCH pathway and cites: and: but neither summary nor is available here for citation. Coverage debug shows 7 articles considered and 0 after recent evidence window. Service-provider context alone is not directional proof without retained positive or negative evidence.

Thesis: No positive thesis can be supported because there is no retained direct positive evidence within the reviewed sources' recent evidence window.

Why now: No current business change or catalyst is evidenced in the retained rows.

Caveats: Phase-2 rationale references: about analysis of satellite maneuvers near an ICEYE satellite, but no or article summary is provided here for citation. Coverage debug shows 1 article considered and 0 after recent evidence window. Single-article descriptive context in phase-2 rationale is weaker than direct event/fact evidence and is uncitable here due to missing.

Thesis: No admissible direct positive evidence was available inside the 90-day recent evidence window, so there is no supportable positive 1 year+ opportunity thesis from these reviewed sources alone.

Why now: There is no usable current evidence in the reviewed sources for this company: evidence recent evidence review no current evidence was retained and coverage data shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale references article: but no company-specific evidence are available for ranking use. unavailable in reviewed sources.

Caveats: Reviewed evidence provides no post-recent evidence window evidence. Membership rationale is not directional proof. Referenced: has no in the reviewed sources.

Thesis: Kepler may have long-horizon potential because the membership rationale says it operates an optical relay satellite network and is prime contractor on ESA HydRON optical communications work, but there is no available within the recent evidence window evidence in these reviewed sources to substantiate a directional score.

Why now: There is no scoreable current catalyst because the reviewed sources contain no reviewed evidence after the 90-day recent evidence filter for this company.

Caveats: Membership rationale cites, and, but the supporting article details are not available here. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. No current dated evidence means recency is uncertain.

Thesis: Reviewed evidence hints only that Kessler Dynamics was listed in a spacetech accelerator with themes including rocket propulsion, satellites, and space energy, but no in-recent evidence window direct evidence or article is provided, so there is no supported positive thesis.

Why now: There is no usable dated catalyst evidence in the reviewed sources for the 1 year+ horizon. The reviewed sources show 0 reviewed evidence after the 90-day cutoff and no representative article summary or for direct citation.

Caveats: Coverage is effectively empty after recent evidence filtering: evidence recent evidence review shows kept_rows 0 and coverage data shows evidence after recent evidence window 0. The reviewed sources references support references including: but no or quote/summary is provided, so it cannot support factual claims under the citation rule.

Thesis: No direct positive evidence is available, so there is no supportable opportunity thesis from these reviewed sources alone.

Why now: The only described context is that Intuitive Machines 'closed KinetX transaction' in article, but no business description, no, and no evidence are available after recent evidence filtering.

Caveats: Acquisition context alone is not directional proof for KinetX. No company-specific operating facts are available. Referenced has no in the reviewed sources.

Thesis: Execution risk remains meaningful because the key value inflection still depends on MIURA 5 development and inaugural test-flight timing later in 2026 rather than already-proven orbital commercial cadence.

Why now: The reviewed sources show a sequence of material developments: €180 million Series C on March 4, 2026, €30 million EIB venture debt signed April 7, 2026 and reported May 6, 2026/04-07, first commercial contract reported May 21, 2026, and €35 million Kourou launch-complex investment on June 1, 2026 while MIURA 5 remained on track for a late-2026 first test flight. That is strong state-change evidence for a 1 year+ horizon.

Caveats: Risk evidence is partly inferred from dependency on future launch milestones rather than a disclosed adverse event. Most support is supporting article context, though the chronology is consistent and material.

Thesis: Risk is moderate because the reviewed sources' key opportunity is still relatively early in size and scope compared with SpaceX, and execution must extend from launch into GEO satellite production and operation.

Why now: The main catalyst is the May 2026 award of Rocket Lab's first GEO satellite production program for the U.S. Space Force, which extends the company into a new orbital regime and broadens its mission model. That is paired with evidence of ongoing launch execution on May 22, 2026 through the ninth dedicated Electron mission for Synspective.

Caveats: The reviewed sources contain no direct negative events, so risk is mainly execution-based rather than explicitly evidenced adverse news. One representative item references stock performance but is undated and should not be treated as reliable recency proof.

Thesis: Risk remains meaningful because the reviewed sources classifies the available evidence mostly as weak supporting article context rather than direct positive events/facts, and there is no available direct evidence for commercial revenue conversion, deployment success, or execution milestones beyond the grant and partnership narratives

Why now: Why now is strong because the June 11-22, 2026 evidence sequence shows fresh capital support first, then a later strategic partnership, suggesting opportunity maturation within weeks rather than stale background context

Caveats: Most evidence is supporting article context or weak context rather than direct positive events. Same-story repetition around the grant should not be treated as independent confirmation. No direct available evidence of revenue, backlog conversion, or deployment milestones.

Thesis: Risk remains meaningful because the reviewed sources' usable support is mostly supporting article context rather than direct positive events, and the financing is growth capital for a private company rather than proof of commercial conversion at scale.

Why now: A dated May 6, 2026 article says Scout raised up to $18 million Series A and will use the capital for mission execution and expansion of manufacturing capabilities, creating a current capacity-building milestone for the next year, May 6, 2026).

Caveats: Most available support is weak context/supporting article context rather than direct positive events. Blue Origin partnership articles are from 2025 and were outside the 90-day recent evidence window, so they should not drive recency-based ranking

Thesis: The main risk is launch execution risk because the reviewed sources frames Vikram-1 as a preparation-stage maiden orbital mission rather than an already completed orbital launch, and there is no additional direct evidence in the reviewed sources showing later de-risking.

Why now: The relevant dated development is the reported financing on May 7, 2026 alongside the stated approach to the Vikram-1 maiden flight, which fits a 1 year+ thesis if execution progresses.

Caveats: Support is supporting article context only; the reviewed sources have no direct positive events available for Skyroot. Same-article repeated context rows are not independent confirmation.

Thesis: Risk exists from concentration in large government programs and evidence of pricing tension with the Pentagon, but the reviewed sources does not show a material adverse operational or financial event inside the recent evidence window.

Why now: The timing is supported by late-May 2026 contract awards: a $2.29 billion Space Force data-network award dated May 26, 2026 and a $4.16 billion Space Force SB-AMTI award dated May 29, 2026/May 30, 2026, plus NASA's plan dated May 24, 2026 to add missions to SpaceX's commercial crew contract, all of which indicate durable backlog expansion and franchise entrenchment over a 1 year+ horizon.

Caveats: The reviewed sources' available source fields contain no direct positive or negative events for SpaceX; opportunity is inferred from high-materiality neutral facts and article summaries. Ticker mapping is noisy in the reviewed sources: SpaceX is shown with ticker TSLA, which should not be treated as validated public-company identity here.

Thesis: The same constellation-buildout framing also implies material execution risk because the reviewed sources provide no fresh in-window evidence confirming funding sufficiency, deployment timing, customer demand, or progress beyond the build statement.

Why now: There is no direct, dated catalyst in the available evidence. The reviewed sources references article ID: for membership support, but provides no and shows 0 evidence after recent evidence window, so current status cannot be verified.

Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources does not include a or summary for citation.

Thesis: Risk is modestly higher than opportunity because there is effectively no fresh reviewed evidence to validate current traction, contracts, or program wins after the March 29, 2026 cutoff. The issue is not reviewed sources-proven deterioration, but lack of current support.

Why now: There is no current catalyst in the kept ranking evidence. The only representative article provided is dated February 7, 2025, outside the recent evidence window, via at

Caveats: Zero evidence were kept after the 90-day recent evidence window. The available article context is outside recent evidence window and should not be treated as current catalyst evidence.

Thesis: Starcloud also carries meaningful execution risk because the reviewed sources evidence frames the business around an extremely ambitious proposed constellation scale and supporting article context rather than direct company events. The May 26, 2026 article says the constellation ultimately envisions 88,000 orbital data centers, a very large scope that implies substantial execution and capital intensity risk.

Why now: Within the 90-day recent evidence window, Starcloud has the clearest sequence of dated business-state updates: funding on March 30, 2026, network-equipment contract on May 26, 2026, and additional context on capital raised and market positioning on June 10, 2026, For a 1 year+ horizon, that sequence supports an active buildout story even though evidence quality is not fully direct.

Caveats: All usable evidence is supporting article context; the reviewed sources provide no direct positive or negative dated event/facts. Repeated Starcloud claims across articles are not independent confirmation under the evidence standard. Opportunity and risk both remain dependent on future execution over a long horizon.

Thesis: The same rationale also implies significant technology and commercialization risk: pre-seed stage, advanced propulsion development, and no available proof of contracts, flight validation, or revenue traction in the reviewed sources.

Why now: Why now is relatively better than peers because the rationale includes a recent capital raise and a specific product focus, both of which can influence a 1 year+ strategic trajectory, though no direct dated evidence are available to verify recency sequencing.

Caveats: Membership rationale cites article IDs: and: but no are present. The reviewed sources contain no direct positive or negative evidence arrays despite the financing statement in the rationale. Early-stage propulsion development is inherently high-uncertainty, but that is inferred from stage and product type, not from a available adverse article.

Thesis: Risk is modest because there is too little available evidence after recent evidence window to support a stronger positive or negative view, making outcome uncertainty high.

Why now: The membership rationale references selection for IN-SPACe funding and AI-powered star tracker work using article IDs, and: but no article summaries, or direct evidence are available in these reviewed sources after recent evidence window, so recency and materiality cannot be independently verified from the evidence body.

Caveats: No representative articles, or available evidence available to cite directly beyond membership rationale. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Scoring is conservative because reviewed sources support is incomplete in the visible evidence section.

Thesis: Risk remains meaningful because the reviewed sources provide only thin support beyond the financing statement; there is no available kept direct positive event detail, customer traction, deployment milestone, or contract evidence to validate execution progress.

Why now: The 'why now' is the capital raise described in the reviewed sources' membership rationale via article: but the ranking payload does not include the article or a richer reviewed evidence row, so recency and detail are only partially grounded.

Caveats: The reviewed sources does not provide the article for the cited membership-support article. This is mainly a financing-backed opportunity thesis, not a contract- or revenue-backed one in these reviewed sources.

Thesis: Risk is moderately elevated because, despite the promising rationale, the reviewed sources show no representative article details, no direct positive evidence, and zero article IDs after recent evidence window in coverage debug. That creates substantial verification and timing uncertainty.

Why now: Why now is only moderate because the membership rationale references support references including, and: but the reviewed sources does not provide or article summaries for them. Without visible dated article detail, the near-current business state cannot be confirmed.

Caveats: Important claims appear only in the membership rationale; no -bearing direct evidence is exposed. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0.

Thesis: Risk remains meaningful because the company is tied to a demanding defense-space interceptor effort, and one source notes $50 million of the financing was debt, which adds some balance-sheet/obligation risk. In addition, much of the evidence comes from external articles and company-associated announcements rather than a broader set of independently available direct events.

Why now: The recent sequence matters: on April 28, 2026, True Anomaly announced a $650 million Series D at a $2.2 billion valuation, also. Then on May 4, 2026, a dated article said the company was selected by the U.S. Space Force Space Systems Command for the Space-Based Interceptor program. That capital-plus-program sequence is directly relevant to a long-horizon growth thesis.

Caveats: Most evidence is external overlay context/facts rather than primary data source direct events. Several sources repeat the same April 28 financing story and are not independent confirmation of different events. The company-site article is undated, so recency-sensitive claims from it should be treated cautiously.

Thesis: Even with the stated Series B and launch success, launch-vehicle companies remain execution- and capital-intensive, and the reviewed sources provide no available evidence on follow-on contracts, cadence, or economics. Risk is therefore still elevated.

Why now: Why now is relatively stronger because the rationale includes both funding and a technical milestone, which are durable indicators for a 1 year+ horizon, though exact dates and chronology cannot be checked from the reviewed sources' empty post-recent evidence window evidence tables.

Caveats: Membership rationale cites article IDs: and: but no are given. No direct events or summaries are available after recent evidence window, so success claims cannot be quoted from the reviewed sources. Opportunity and risk both reflect a capital-intensive launch model with limited reviewed sources verification.

Thesis: The same evidence implies meaningful execution risk: building a satellite network is capital intensive and ambitious, while the reviewed sources offers only one supporting article and no direct follow-on customer, launch, or technical milestone evidence.

Why now: Why now is the claimed funding event and network build plan referenced in article ID: but the reviewed sources does not provide the article or detailed timestamp, so recency is only partially grounded.

Caveats: The key claim comes from membership rationale rather than available direct evidence. Article ID: is referenced without a. No evidence of downstream execution, contracts, launches, or adoption is present.

Thesis: Risk is elevated because the reviewed sources does not expose the underlying article summaries or -bearing evidence for those contract claims inside the ranking section, and coverage debug shows zero article IDs after recent evidence window and zero evidence available after recent evidence window. That leaves execution and verification risk high.

Why now: Why now is only moderate because the membership rationale references significant contracts via support references including: but the reviewed sources provide no or representative article detail for citation-quality corroboration. The forecast horizon of 1 year+ could fit contract conversion and constellation expansion if current, but recency cannot be validated from visible article rows.

Caveats: The contract and expansion claims appear only in membership rationale text; no representative article with is included. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0.

Thesis: Risk remains elevated because the same body of context portrays Vast as pursuing multiple capital-intensive initiatives at once—commercial space stations, NASA contract competition, and now satellite manufacturing. Earlier dated March items about a $500 million raise were outside the recent evidence window and therefore cannot be primary support here, so the retained case still relies on supporting article context rather than direct event/facts, leaving execution and commercialization risk significant, May 19, 2026, May 19, 2026).

Why now: The timing case is stronger than peers because the product expansion articles are dated May 19, 2026 and May 20, 2026, within the 90-day recent evidence window, and represent a potentially durable strategic change: moving into satellite buses rather than remaining only a station developer, May 19, 2026, May 20, 2026).

Caveats: Retained evidence is weak context supporting article context; there are no direct positive event/facts available. The March 2026 financing articles are outside the 90-day recent evidence window and cannot be primary support, even though they appear in representative articles. Several retained rows summarize the same basic product announcement and should not be treated as independent confirmation.

Thesis: Execution risk appears elevated because the thesis depends on a planned constellation and post-quantum satellite rollout, yet the reviewed sources lack fresh evidence validating current status. With no direct negative event available, the risk score is driven by uncertainty around plan-to-execution conversion rather than confirmed deterioration.

Why now: There is no documented near-term catalyst in the available evidence. Membership support cites article IDs and, but the reviewed sources reports 0 article IDs after recent evidence window and 0 evidence after recent evidence window.

Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article IDs and, but the reviewed sources does not include or article summaries for citation. Risk is inferred from lack of current execution proof, not from a confirmed adverse event.

Thesis: Risk is moderate because the available evidence is undated supporting article context from the company site. Since the basis is explicitly 'undated,' recency-sensitive claims about current constellation readiness, capacity, and commercial position are uncertain.

Why now: Why now is weak because the evidence retained is undated and the reviewed sources explicitly says to treat recency-sensitive claims cautiously when no is available. The underlying strategic area may be attractive, but current business-state confirmation is missing.

Caveats: Evidence is undated, so current-state claims are less reliable for timing judgments. Only supporting article context is provided, not direct event evidence. No direct customer, contract, financing, or negative-event evidence is shown.